Skip to main content
Quest Diagnostics

Pseudoendocrine Sarcoma: Clinicopathologic, Molecular, and Epigenetic Features of One Case

Pseudoendocrine Sarcoma: Clinicopathologic, Molecular, and Epigenetic Features of One Case

Authors: Vizcaino MA, Folpe AL, Huffman H, Panchal RR, Nielsen GP, Kipp BR, Turakulov R, Aldape K, Giannini C

Citation: Virchows Arch. 2023 Nov 13. doi: 10.1007/s00428-023-03695-3. Online ahead of print.

Specialties: Dermatology

Disclaimer: One or more of the authors of this publication were employed at the time by AmeriPath, a subsidiary of Quest Diagnostics.

Related content

Audio Podcast
Optimize Oncology Care with Clinical Pathways
Publication
High-Resolution Targeted Bisulfite Sequencing Reveals Blood Cell Type-Specific DNA Methylation Patterns in IL13 and ORMDL3

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.